Daniel A. Weintraub
#129,067
Most Influential Person Now
Daniel A. Weintraub's AcademicInfluence.com Rankings
Daniel A. Weintraubphilosophy Degrees
Philosophy
#6187
World Rank
#9184
Historical Rank
Logic
#3380
World Rank
#4527
Historical Rank
Daniel A. Weintraubbiology Degrees
Biology
#8379
World Rank
#11447
Historical Rank
Neuroscience
#1153
World Rank
#1195
Historical Rank
Download Badge
Philosophy Biology
Daniel A. Weintraub's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Neuroscience University of California, San Francisco
Why Is Daniel A. Weintraub Influential?
(Suggest an Edit or Addition)Daniel A. Weintraub's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines (2012) (1851)
- Diagnosis and management of dementia with Lewy bodies (2017) (1606)
- Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. (2010) (1265)
- The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease (2011) (1005)
- Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease (2009) (919)
- Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. (2006) (887)
- MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI (2011) (700)
- Association of dopamine agonist use with impulse control disorders in Parkinson disease. (2006) (635)
- Depression rating scales in Parkinson's disease: Critique and recommendations (2007) (616)
- Cognitive decline in Parkinson disease (2017) (608)
- Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy (2017) (502)
- Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review (2019) (492)
- Mild cognitive impairment in Parkinson disease (2010) (443)
- Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial (2010) (443)
- Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. (2014) (406)
- Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson's Disease (2004) (391)
- Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease (2009) (390)
- Impulse control disorders in parkinson disease: A multicenter case–control study (2011) (389)
- Parkinson's disease: The quintessential neuropsychiatric disorder (2011) (343)
- Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated (2018) (338)
- Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis (2017) (329)
- CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease (2010) (314)
- Montreal Cognitive Assessment Performance in Patients with Parkinson's Disease with “Normal” Global Cognition According to Mini‐Mental State Examination Score (2009) (310)
- Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations (2008) (292)
- APOE ε4 increases risk for dementia in pure synucleinopathies. (2013) (282)
- The impact of depressive symptoms in early Parkinson disease (2007) (270)
- Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study (2017) (262)
- Clinical spectrum of impulse control disorders in Parkinson's disease (2015) (257)
- Questionnaire for impulsive‐compulsive disorders in Parkinson's Disease–Rating Scale (2012) (253)
- Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. (2008) (248)
- Anxiety rating scales in Parkinson's disease: Critique and recommendations (2008) (242)
- Long‐term follow‐up of impulse control disorders in Parkinson's disease (2008) (234)
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
- Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. (2005) (232)
- Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease (2010) (226)
- The psychosis spectrum in Parkinson disease (2017) (224)
- Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease (2015) (223)
- Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. (2006) (221)
- Sertraline for the treatment of depression in Alzheimer disease. (2010) (204)
- Impulse Control and Related Disorders in Parkinson's Disease. (2017) (200)
- Recognition and Treatment of Depression in Parkinson's Disease (2003) (196)
- Neurodegeneration across stages of cognitive decline in Parkinson disease. (2011) (194)
- Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group (2014) (193)
- Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. (2009) (188)
- Antidepressant studies in Parkinson's disease: A review and meta‐analysis (2005) (186)
- APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. (2014) (175)
- Dopamine and impulse control disorders in Parkinson's disease (2008) (174)
- Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study (2015) (172)
- Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. (2016) (172)
- CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study (2016) (169)
- Longitudinal study of normal cognition in Parkinson disease (2015) (168)
- Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. (2015) (162)
- Initial cognitive decline is associated with cortical thinning in early Parkinson disease (2014) (160)
- GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease (2016) (157)
- Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. (2012) (156)
- The Parkinson Anxiety Scale (PAS): Development and validation of a new anxiety scale (2014) (155)
- [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease (2005) (148)
- Impulsive and compulsive behaviors in Parkinson's disease (2009) (146)
- Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study (2010) (145)
- Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease (2011) (144)
- Association between cognition and function in patients with Parkinson disease with and without dementia (2010) (142)
- Defining and Diagnosing Involuntary Emotional Expression Disorder (2006) (141)
- Parkinson disease-associated cognitive impairment (2021) (141)
- Psychiatric complications in Parkinson disease. (2005) (139)
- Decreased ventral striatal activity with impulse control disorders in Parkinson's disease (2010) (139)
- Task force report: Scales for screening and evaluating tremor: Critique and recommendations (2013) (130)
- Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders (2019) (130)
- Cognitive impairment in nondemented Parkinson's disease (2011) (128)
- Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. (2010) (126)
- Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson’s disease: results from a randomised, controlled trial (2013) (124)
- Global scales for cognitive screening in Parkinson's disease: Critique and recommendations (2018) (123)
- Genetic influences on cognitive decline in Parkinson's disease (2012) (122)
- Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. (2016) (121)
- Evidence for Impaired Encoding and Retrieval Memory Profiles in Parkinson Disease (2004) (117)
- New evidence on the management of Lewy body dementia (2020) (116)
- Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort (2018) (113)
- Psychosis in Parkinson's disease without dementia: Common and comorbid with other non‐motor symptoms (2012) (110)
- Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases (2017) (109)
- Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. (2003) (107)
- Suicidal and death ideation in Parkinson's disease (2008) (107)
- Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology (2018) (106)
- Screening for impulse control symptoms in patients with de novo Parkinson disease (2013) (106)
- Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease (2017) (105)
- Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts (2019) (97)
- Course of psychiatric symptoms and global cognition in early Parkinson disease (2014) (97)
- Diagnosis and management of Parkinson's disease dementia (2008) (97)
- Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease (2015) (95)
- MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study (2016) (95)
- Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. (2011) (95)
- Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study (2015) (92)
- Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. (2009) (91)
- Olfactory impairment predicts cognitive decline in early Parkinson's disease. (2016) (90)
- Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease (2007) (89)
- Dimensions of Executive Function in Parkinson’s Disease (2005) (89)
- Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: prevalence, depression, and personality. (2014) (88)
- Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. (2016) (88)
- Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. (2015) (88)
- Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. (2007) (87)
- A Consensus Set of Outcomes for Parkinson’s Disease from the International Consortium for Health Outcomes Measurement (2017) (85)
- Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases (2017) (84)
- Conversion between Mini‐Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale‐2 scores in Parkinson's disease (2014) (83)
- Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. (2019) (82)
- Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease (2016) (82)
- Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort (2017) (81)
- Parkinson's disease‐related fatigue: A case definition and recommendations for clinical research (2016) (81)
- CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease (2015) (80)
- Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology (2018) (78)
- Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease (2015) (76)
- Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease (2019) (76)
- People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance (2014) (74)
- Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression (2020) (73)
- Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
- Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease (2011) (71)
- The Neuropsychiatry of Parkinson Disease: A Perfect Storm. (2019) (71)
- Effect of age on geriatric depression scale performance in Parkinson's disease (2007) (70)
- High patient satisfaction with telehealth in Parkinson disease: A randomized controlled study (2016) (69)
- Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders (2018) (69)
- A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short‐ and long‐acting dopamine agonists (2016) (68)
- Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. (2011) (66)
- Advances in the treatment of cognitive impairment in Parkinson's disease (2015) (66)
- Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. (2016) (65)
- Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative (2017) (64)
- Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. (2017) (62)
- Fatigue in Parkinson’s disease: report from a mutidisciplinary symposium (2016) (60)
- CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders (2018) (59)
- Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. (2016) (59)
- Arguing against the proposed definition changes of PD (2016) (58)
- Parkinson's disease--Part 3: Neuropsychiatric symptoms. (2008) (58)
- Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease (2016) (57)
- Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease (2018) (55)
- Cognitive profile of LRRK2‐related Parkinson's disease (2015) (55)
- Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial (2014) (55)
- Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)? (2011) (54)
- Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trial (2016) (53)
- Antidepressant Treatment of Veterans With Parkinson's Disease and Depression: Analysis of a National Sample (2007) (53)
- Genetic risk of Parkinson disease and progression: (2019) (53)
- Citalopram for agitation in Alzheimer’s disease: Design and methods (2012) (52)
- Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease (QUIP) and the QUIP-rating scale in a German speaking sample (2014) (50)
- Treatment of Early Parkinson’s Disease (2009) (50)
- Impulse control disorder related behaviours during long‐term rotigotine treatment: a post hoc analysis (2016) (49)
- Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease (2016) (49)
- Assessing the Executive Function Deficits of Patients with Parkinson’s Disease (2004) (48)
- Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. (2012) (48)
- Psychiatric issues in cognitive impairment (2014) (47)
- Attitudes Regarding the Etiology and Treatment of Depression in Parkinson's Disease: A Qualitative Study (2008) (47)
- Impulse Control and Related Disorders in Parkinson’s Disease (2012) (46)
- The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study (2020) (46)
- Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings (2016) (45)
- Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. (2016) (44)
- Parkinson's disease--Part 2: Treatment of motor symptoms. (2008) (44)
- The course of depressive symptoms in early Parkinson's disease (2009) (43)
- Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. (2006) (42)
- Initial cognitive changes in Parkinson's disease (2018) (42)
- Novel conformation‐selective alpha‐synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease (2017) (42)
- Impulse control and related disorders in Mexican Parkinson's disease patients. (2014) (42)
- Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. (2006) (41)
- The neuropsychiatry of Parkinson's disease: advances and challenges (2022) (41)
- Optimizing olfactory testing for the diagnosis of Parkinson’s disease: item analysis of the university of Pennsylvania smell identification test (2018) (40)
- The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. (2016) (39)
- TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia (2019) (39)
- Rivastigmine in Alzheimer’s Disease and Parkinson’s Disease Dementia (2011) (39)
- Differences in the Presentation and Progression of Parkinson's Disease by Sex (2020) (39)
- Cognition among individuals along a spectrum of increased risk for Parkinson’s disease (2018) (38)
- Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study (2020) (38)
- Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease (2018) (38)
- Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. (2015) (37)
- Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests (2018) (37)
- APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease (2018) (37)
- Geriatric patients on a substance abuse consultation service. (2002) (37)
- Bridging cognitive screening tests in neurologic disorders: A crosswalk between the short Montreal Cognitive Assessment and Mini-Mental State Examination (2017) (37)
- Longitudinal decline in speech production in Parkinson's disease spectrum disorders (2017) (36)
- Naltrexone for impulse control disorders in Parkinson disease (2014) (36)
- Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease (2020) (36)
- Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease (2018) (36)
- Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype (2015) (35)
- Cognition and the course of prodromal Parkinson's disease (2017) (35)
- Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression (2019) (35)
- Electroconvulsive therapy for depression in a Parkinson's disease patient with bilateral subthalamic nucleus deep brain stimulators. (2005) (35)
- A Cross-Sectional Study of 3090 Patients (2010) (35)
- The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease. (2017) (34)
- Anxiety has specific syndromal profiles in Parkinson disease: a data-driven approach. (2014) (34)
- Is depression in Parkinson's disease (PD) a specific entity? (2012) (34)
- Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations (2019) (34)
- Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease (2019) (34)
- Caregiver report of apathy predicts dementia in Parkinson's disease. (2015) (33)
- Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease (2016) (33)
- Impulse control disorders in parkinson’s disease (2006) (33)
- Trial of Pimavanserin in Dementia-Related Psychosis. (2021) (33)
- International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease (2021) (33)
- Risk of Parkinson's disease dementia related to level I MDS PD‐MCI (2019) (32)
- Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease (2021) (32)
- An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia (2016) (32)
- Medication Management and Neuropsychological Performance in Parkinson's Disease (2012) (32)
- Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease (2020) (32)
- Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking (2015) (31)
- Characterization of Parkinson’s disease using blood-based biomarkers: A multicohort proteomic analysis (2019) (31)
- Depression in veterans with Parkinson's disease: frequency, co‐morbidity, and healthcare utilization (2007) (31)
- Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia (2017) (31)
- Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations (2021) (31)
- The Non‐Motor Symptoms Scale in Parkinson’s disease: Validation and use (2020) (31)
- Benefit finding and relationship quality in Parkinson's disease: a pilot dyadic analysis of husbands and wives. (2014) (30)
- Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype (2016) (30)
- GPNMB confers risk for Parkinson’s disease through interaction with α-synuclein (2022) (29)
- Cognitive impairment and PD patients' capacity to consent to research (2013) (29)
- Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications (2018) (28)
- Antipsychotic Use and Physical Morbidity in Parkinson Disease. (2017) (28)
- Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? (2013) (27)
- Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder (2020) (27)
- R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. (2016) (27)
- Predictors of anxiety in early-stage Parkinson's disease - Results from the first two years of a prospective cohort study. (2017) (26)
- Amyloid‐Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia (2016) (26)
- Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease. (2009) (25)
- Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. (2015) (25)
- Frequency and correlates of involuntary emotional expression disorder in Parkinson's disease. (2009) (25)
- Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease (2017) (25)
- Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder (2018) (23)
- Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial (2015) (23)
- Neuropsychologic assessment in collaborative Parkinson’s disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson’s Disease Research at the University of Pennsylvania and the University of Washington (2013) (23)
- Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15‐item Geriatric Depression Scale (GDS‐15) (2007) (22)
- Pilot Study of the International Parkinson and Movement Disorder Society‐sponsored Non‐motor Rating Scale (MDS‐NMS) (2019) (21)
- Phenylthiocarbamide (PTC) Perception in Parkinson Disease (2007) (21)
- Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer’s Disease (2018) (21)
- Case for and against specificity of depression in Alzheimer's disease (2010) (20)
- Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy (2017) (20)
- Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report (2015) (20)
- Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. (2017) (20)
- Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. (2021) (20)
- Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. (2017) (20)
- Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire (2016) (20)
- Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine? (2020) (19)
- Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable. (2014) (18)
- Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. (2014) (18)
- Prevalence of Non‐Motor Symptoms and Non‐Motor Fluctuations in Parkinson's Disease Using the MDS‐NMS (2020) (18)
- Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. (2016) (18)
- Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body Dementias (2021) (17)
- Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis (2013) (17)
- Cognition in movement disorders: Where can we hope to be in ten years? (2014) (17)
- The Case for Antipsychotics in Dementia with Lewy Bodies (2017) (17)
- Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson’s disease (2020) (17)
- Pattern of Depressive Symptoms in Parkinson's Disease (2009) (17)
- Involuntary emotional expression disorder (IEED) in Parkinson's disease. (2009) (17)
- Daily affect in Parkinson disease is responsive to life events and motor symptoms. (2006) (17)
- Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinson’s Disease and Cross-Cultural Comparison (2018) (16)
- Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment (2021) (16)
- Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. (2019) (16)
- Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease (2019) (15)
- Impulse control disorders in Parkinson's disease: A 20‐year odyssey (2019) (15)
- Validation of a performance‐based assessment of cognitive functional ability in Parkinson's disease (2018) (15)
- Sertraline for the Treatment of Depression in Alzheimer Disease: Genetic Influences (2011) (14)
- Pharmacologic Management of Psychosis in the Elderly: A Critical Review (2003) (14)
- Selection of Normative Group Affects Rates of Mild Cognitive Impairment in Parkinson's Disease (2018) (13)
- Integration and Extension of Specialty Mental Healthcare Services to Community Practice in Parkinson Disease. (2019) (13)
- Management of psychiatric disorders in Parkinson’s disease (2020) (13)
- The American Psychiatric Publishing Textbook of Geriatric Neuropsychiatry (2011) (13)
- Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. (2014) (13)
- Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer’s disease (2020) (13)
- Research consent capacity varies with executive function and memory in Parkinson's disease (2016) (12)
- A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation (2015) (12)
- Tau pathology associates with in vivo cortical thinning in Lewy body disorders (2020) (12)
- Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases: evidence about efficacy and safety. (2005) (12)
- Citalopram for the Treatment of Agitation in Alzheimer Dementia (2016) (12)
- Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants (2019) (12)
- Altered large-scale functional brain networks in neurological Wilson’s disease (2020) (12)
- Pharmacological treatment of apathy in Lewy body disorders: A systematic review. (2019) (12)
- 1.003 FACILITATING CLINICAL RESEARCH: THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS (NINDS) AND STROKE PARKINSON'S DISEASE COMMON DATA ELEMENTS PROJECT (2012) (12)
- Impulse control and related behaviors in Parkinson’s disease with dementia (2020) (12)
- Statins and Cognition in Parkinson's Disease. (2017) (12)
- Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
- Diagnosing and Treating Depression in Patients With Parkinson's Disease (2004) (11)
- Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease (2019) (11)
- Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine (2019) (11)
- Effect of Increasing the Dose and Duration of Sertraline Trial in the Treatment of Depressed Nursing Home Residents (2003) (11)
- Second‐Generation Issues in the Management of Depression in Nursing Homes (2002) (11)
- From action to abstraction: The sensorimotor grounding of metaphor in Parkinson's disease (2019) (11)
- Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management (2013) (11)
- Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta‐Analysis (2016) (10)
- Pattern of depressive symptoms in Parkinson's disease. (2009) (10)
- Hospital care for mental health and substance abuse conditions in Parkinson's disease (2016) (10)
- RECOGNITION AND TREATMENT OF DEPRESSION IN PARKINSONS DISEASE (2003) (9)
- Depression and Coexisting Medical Disorders in Late Life (2002) (9)
- Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset (2021) (9)
- Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum (2021) (8)
- Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours (2011) (8)
- Neuropsychiatric and cognitive disorders in other parkinsonian disorders (2013) (8)
- Identifying Parkinson’s disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering (2021) (8)
- Introduction: The importance of cognition in movement disorders (2014) (7)
- Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (2018) (7)
- Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology (2017) (7)
- Reply: Mild cognitive impairment in de novo Parkinson's disease according to Movement Disorder guidelines (2012) (7)
- Low continuation of antipsychotic therapy in Parkinson disease – intolerance, ineffectiveness, or inertia? (2021) (7)
- Change in the Rate of Restraint Use and Falls on a Psychogeriatric Inpatient Unit: Impact of the Health Care Financing Administration's New Restraint and Seclusion Standards for Hospitals (2002) (7)
- Impulse control disorders in Parkinson's disease. (2019) (7)
- ADNC-RS, a clinical-genetic risk score, predicts Alzheimer’s pathology in autopsy-confirmed Parkinson’s disease and Dementia with Lewy bodies (2020) (7)
- Citalopram compared to atypical antipsychotics for Alzheimer patients who did not previously benefit from treatment: The catie-AD study (2009) (7)
- Early cognitive impairment (2013) (7)
- French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). (2019) (7)
- Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson's Disease Patients: A Case-Control Study. (2018) (7)
- Glad about SAD (PD) (2012) (7)
- Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx). (2016) (6)
- Is Rapid Eye Movement Sleep Behavior Disorder a Risk Factor for Impulse Control Disorder in Parkinson Disease? (2020) (6)
- The depressed brain in Parkinson's disease: Implications for an inflammatory biomarker (2017) (6)
- Direct Medical Costs of Dementia With Lewy Bodies by Disease Complexity. (2020) (6)
- Neuropsychiatric symptoms in Parkinson disease and dementia with Lewy bodies: what geriatric psychiatry can learn. (2013) (6)
- Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease (2021) (6)
- The 36-Hour Day (3rd Edition) (2001) (6)
- Disorders of mood and affect in Parkinson's disease. (2007) (6)
- 3D Convolutional Neural Networks for Classification of Alzheimer’s and Parkinson’s Disease with T1-Weighted Brain MRI (2021) (6)
- Is the Parkinson anxiety scale comparable across raters? (2015) (6)
- Genetic prediction of impulse control disorders in Parkinson's disease (2022) (5)
- Treatment of Early Parkinson’s Disease (2009) (5)
- Medicare Claims Data Underestimate Hallucinations in Older Adults With Dementia. (2021) (5)
- An International Multicenter Analysis of Brain Structure across Clinical Stages of Parkinson's Disease: The ENIGMA-Parkinson's Study (2020) (5)
- Intervening in the neuropsychiatric features of Parkinson’s disease (2007) (5)
- Plasma Phosphorylated Tau181 is a Biomarker of Alzheimer's Disease Pathology and Associated with Cognitive and Functional Decline (2022) (5)
- Author Correction: Parkinson disease-associated cognitive impairment (2021) (5)
- Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting (2022) (5)
- Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease (2019) (5)
- Frequency of and risk factors for potentially inappropriate medication use in Parkinson's disease. (2020) (4)
- Measurement properties from the Brazilian Portuguese version of the QUIP-RS (2020) (4)
- Cross-Sectional and Longitudinal Validation of Serum Neurofilament Light Chain (NfL) as a Biomarker of Parkinson’s Disease Progression (2019) (4)
- Corrigendum: Fatigue in Parkinson’s disease: report from a multidisciplinary symposium (2017) (4)
- Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe? (2021) (4)
- Principal components analysis of agitation outcomes in Alzheimer's disease. (2016) (4)
- Both the body and brain benefit from exercise: Potential win‐win for Parkinson's disease patients (2011) (4)
- The Danger of Not Treating Parkinson Disease Psychosis-Reply. (2016) (4)
- Standard set measuring patient-centred outcomes in Parkinson's disease : an international, cross-disciplinary effort (2015) (4)
- Progress Regarding Parkinson's Disease Psychosis: It's No Illusion (2016) (4)
- Factor Analysis and Clustering of the Movement Disorder Society–Non‐Motor Rating Scale (2020) (4)
- Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease (2021) (3)
- Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease (2021) (3)
- Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease (2022) (3)
- Movement in Aesthetic Experiences: What We Can Learn from Parkinson Disease (2021) (3)
- Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease. (2022) (3)
- Clinical characteristics and course of dlb: Results from a large longitudinal multicentre cohort (2015) (3)
- Frequency and profile of mild cognitive impairment in Parkinson's disease: A multicentre meta-analysis of neuropsychological data (2009) (3)
- Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. (2020) (3)
- Part 2: Treatment of Motor Symptoms (2008) (3)
- Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease. (2020) (3)
- Genome-wide association study of Parkinson’s disease progression biomarkers in 12 longitudinal patients’ cohorts (2019) (3)
- Cognitive decline before diagnosis of Parkinson's disease – Authors' reply (2017) (3)
- Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect (2018) (3)
- Parkinson’s Disease Impulsive-Compulsive Disorders Questionnaire – Current Short (QUIP-CS) – Translation and validation of content of Portuguese Version (2017) (3)
- Validation of the Japanese Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) (2022) (3)
- At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease (2018) (2)
- Diagnosis and Treatment of Cognitive and Neuropsychiatric Symptoms in Parkinson Disease and Dementia With Lewy Bodies (2022) (2)
- A Model to Assess the Outcomes Associated With Dementia With Lewy Bodies. (2020) (2)
- Measurement properties from the Brazilian Portuguese version of the QUIP-RS (2020) (2)
- Management of psychiatric and cognitive complications in Parkinson’s disease (2022) (2)
- Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease (2020) (2)
- Impulse control disorders and related behaviors (2013) (2)
- Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. (2022) (2)
- Therapeutic options for emotional lability: current and emerging treatments. (2005) (2)
- Treatment changes among older patients with dementia treated with antipsychotics (2015) (2)
- Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. (2021) (2)
- Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias. (2022) (2)
- Erratum to: Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease (QUIP) and the QUIP-rating scale in a German speaking sample (2015) (2)
- Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson’s Disease (2020) (2)
- Hallucinations and Development of Dementia in Parkinson's Disease. (2020) (2)
- Neuropsychiatric symptoms in Parkinson’s disease dementia (2010) (2)
- Learning Interpretable Regularized Ordinal Models from 3D Mesh Data for Neurodegenerative Disease Staging (2022) (2)
- A TOMM40 SNP in APOE-ε4 noncarriers increases risk for multiple types of dementia (2013) (1)
- Part 3: Neuropsychiatric Symptoms (2008) (1)
- Management of psychiatric disorders in Parkinson’s disease (2020) (1)
- Psychiatric Complications in Dementia (2006) (1)
- S.14.04 Impulse control disorder: prevalence and possible risk factors (2009) (1)
- Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease (2021) (1)
- Suicidal and death ideation in Parkinson's (2008) (1)
- Efficacy of rasagiline in PD patients with mild cognitive impairment (2016) (1)
- Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting (2022) (1)
- Psychiatric Issues in Parkinson Disease (2021) (1)
- Depression in Parkinson's disease (2005) (1)
- MODERATO, a randomized, double-blind, placebo-controlled study to assess the effect of rasagiline on mild cognitive impairment in patients with Parkinson’s disease: An ongoing study (P3.027) (2015) (1)
- Long-term Outcomes of Parkinson's Disease Patients with Normal Cognition. (P5.260) (2014) (1)
- Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases (2017) (1)
- Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study (2023) (1)
- Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders (2017) (1)
- Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. (2023) (1)
- Atypical antipsychotic use and mortality risk in Parkinson disease. (2022) (1)
- Characterization of Non‐Motor Fluctuations Using the Movement Disorder Society Non‐Motor Rating Scale (2022) (1)
- A Patient-Centered Conceptual Model of Symptoms and Their Impact in Early Parkinson’s Disease: A Qualitative Study (2021) (1)
- Anxiety Syndromes and Panic Attacks (2011) (1)
- CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease (2015) (1)
- RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus (2022) (1)
- 122 Use of Pimavanserin in Patients With Parkinson’s Disease Psychosis: Subgroup Analysis of Efficacy and Safety in Patients With and Without Cognitive Impairment (2018) (1)
- Editorial Advisory Board Co-Editors-in-Chief: (2012) (0)
- LONG-TERM COGNITIVE DECLINE IN DLB IN A LARGE MULTICENTRE, INTERNATIONAL COHORT (2017) (0)
- Erratum: Sertraline for the treatment of depression in Alzheimer disease: Genetic influences (Journal of Geriatric Psychiatry and Neurology (2011) 24:4 (222-228) DOI: 10.1177/0891988711422527) (2012) (0)
- Something Does Not Look Right (2020) (0)
- Assessment of Affective-Behavioral States in Parkinson's Disease Patients: Toward a New Screening Tool. (2021) (0)
- Talking about Family Matters (2020) (0)
- Look below the Surface (EEG) (2020) (0)
- Low Persistence of Antipsychotic Therapy in Parkinson Disease – Intolerance, Ineffectiveness, or Inertia? (2021) (0)
- Apolipoprotein A1 Levels Are Associated with APOA1 Promoter Variation and Influence Parkinson's Disease Risk (S17.004) (2014) (0)
- Course of Impulse Control Disorder Symptoms in Parkinson Disease: Deep Brain Stimulation versus Medications (2023) (0)
- “The Thing about Remembering Names of Things” (2020) (0)
- MODERATO Study to Assess the Effect of Rasagiline on Patients With Parkinson Disease and Mild Cognitive Impairment (2015) (0)
- Pre-proof From action to abstraction : The sensorimotor grounding of metaphor in Parkinson ’ s disease (2019) (0)
- Drug treatment and behavior (2013) (0)
- Difficulty with Language: When Is It Not Aphasia? (2020) (0)
- Perfusion Imaging of Fatigue and Time-on-Task Effects in Patients With Parkinson’s Disease (2022) (0)
- “Memory Is So Good She Will Never Get Dementia” (2020) (0)
- Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease--Rating Scale; French Version (2021) (0)
- Cognitive heterogeneity in Parkinson’s disease: A mechanistic view (2023) (0)
- Regional Distribution of α-Synuclein and Alzheimer’s Disease pathology in Lewy Body Disorders (S45.002) (2018) (0)
- P2.026 Optimizing olfactory testing for the diagnosis of Parkinson's disease (2009) (0)
- You Have Been Diagnosed with Alzheimer Disease; Is That It? (2020) (0)
- Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease (2020) (0)
- “That Is Not How I Feel” (2020) (0)
- A TOMM40 SNP IN APOE E4 NON-CARRIERS INCREASES RISK FOR MULTIPLE TYPES OF DEMENTIA (2013) (0)
- Frontal, Parietal, or Neither? (2020) (0)
- Pseudoatrophic Pattern in Hydrocephalus (2020) (0)
- “This Is Not Like Him” (2020) (0)
- Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression (2019) (0)
- It’s Just Old Age (2020) (0)
- Assessment of heterogeneity and disease onset in the Parkinson's Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study (2023) (0)
- Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study (P2.048) (2018) (0)
- Cognitive decline before diagnosis of Parkinson's disease Reply (2017) (0)
- Aesthetics in motion: The beauty of action paintings as revealed by Parkinson’s disease (2020) (0)
- Is RBD a risk factor for impulse control disorder in Parkinson's disease? (2020) (0)
- Dopamine Agonists vs Levodopa in Impulse Control Disorders—Reply (2011) (0)
- Optimizing olfactory testing for the diagnosis of Parkinson’s disease: item analysis of the university of Pennsylvania smell identification test (2018) (0)
- Plasma phosphorylated tau181 predicts cognitive and functional decline (2022) (0)
- Altered large-scale functional brain networks in neurological Wilson’s disease (2019) (0)
- Update on Management of Psychiatric and Cognitive Symptoms in Parkinson's Disease (2011) (0)
- Does a Positive Amyloid Scan Always Mean Alzheimer Disease? (2020) (0)
- Hallucinations, Antipsychotic Use, and Mortality in Older Adults with Dementia: Retrospective Cohort Study of Two Medicare-Linked National Health Surveys. (2022) (0)
- Part 1: Pathophysiology, Symptoms, Burden, Diagnosis, and Assessment (2008) (0)
- A failure to communicate: Preliminary evidence for cortico‐striatal dysconnection with pathological gambling in Parkinson's disease (2011) (0)
- Cognitive Decline Is Only Part of the Story (2020) (0)
- Prevalence and severity of neuropsychiatric symptoms in the prodromal stages of dementia with Lewy bodies and Alzheimer’s disease (2020) (0)
- Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease (2021) (0)
- Understanding Psychosis in Parkinson's Disease (2014) (0)
- Genetic Variation Near the SNCA Gene Associates with Parkinson’s Disease Motor Endophenotype and Progression (I1.002) (2016) (0)
- Refractory “VGKC Encephalopathy” (2020) (0)
- 2015 Annual Meetings. (2015) (0)
- 0075 Neural Correlates of Cognitive Fatigue in Parkinson Disease (2020) (0)
- A Pause in the Clause (2020) (0)
- Telehealth in the Parkinson's Disease Subspecialty Clinic: The Key to the Patient-Centered Medical Home (P2.048) (2014) (0)
- The Stroke of Clarity (2020) (0)
- Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease (2022) (0)
- “I Have Snored All My Life and It Never Affected My Work” (2020) (0)
- Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder (2018) (0)
- German versions of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease (QUIP) and the QUIP-Rating Scale (2013) (0)
- Clinical features in prodromal disease: Comparing dementia with Lewy bodies with Alzheimer’s disease (2022) (0)
- Efficacy of rasagiline in patients with Parkinson’s disease and mild cognitive impairment: results from moderato, a 24-week randomized, double-blind, placebo-controlled trial (2015) (0)
- The Diagnosis and Longitudinal Course of Common Movement Disorders in Geriatric Psychiatry (2013) (0)
- Imaging and behavior in Parkinson’s disease: structural imaging (2013) (0)
- Parkinson’s disease: pathology, anatomy, and behavior (2013) (0)
- Edinburgh Research Explorer Genetic risk of Parkinson disease and progression: (0)
- It’s Not Alzheimer Disease; Now What? (2020) (0)
- Channeling of New Neuropsychiatric Drugs—Impact on Safety and Effectiveness Studies (2023) (0)
- A Newsletter for the Parkinson ’ s Disease Research , Education and Clinical Centers and The National VA Parkinson ’ s Disease Consortium The VA Parkinson Report (2011) (0)
- Common Pitfalls in Cognitive and Behavioral Neurology (2020) (0)
- Title Common variant rs 356182 near SNCA defines a Parkinson ' s disease endophenotype (2016) (0)
- Clinical Follow‐up of Parkinson's Disease With Newly Prescribed Quetiapine (2020) (0)
- Forum Report International Expert Meeting on the Treatment of Parkinson's Disease 2010 Psychosis in PD パーキンソン病における精神症状(幻覚・妄想) (2011) (0)
- Corticobasal: The Syndrome versus the Pathology (2020) (0)
- “I Have Been Taking the Same Medications for Years” (2020) (0)
- Evaluation of ATNPD framework and biofluid markers to predict cognitive decline in early Parkinson's disease (2023) (0)
- Recognizing the Right Signs of Memory Impairment (2020) (0)
- Automatic analysis and validation of digitized speech markers in Lewy body spectrum diseases with Alzheimer’s disease co‐pathology (2021) (0)
- New Strategies to Optimize Care for Patients With CME Monograph Parkinson ’ s Disease Psychosis FINDING BALANCE : (0)
- Comparison of Patient and Caregiver Assessments of Patient Disability in Parkinson's Disease (P04.186) (2013) (0)
- Drs. Weintraub and Hurtig Reply. (2008) (0)
- sCJD with Negative 14–3–3? (2020) (0)
- Non-negative matrix factorization evaluation of patterns of brain Aβ deposition in Parkinson’s disease, Alzheimer’s disease and normal controls on [18F]florbetapir PET (2018) (0)
- Treatment of Psychosis in Lewy Body Disease. Authors' reply (2008) (0)
- Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies. (2022) (0)
- LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts (2023) (0)
- Parkinsonism, Ataxia, and Cognitive Impairment after Radiation Therapy (2020) (0)
- CSF Aβ1-42 predicts cognitive impairment in de novo PD patients (S32.009) (2015) (0)
- Remembering That We Forget versus Forgetting Altogether (2020) (0)
- The Disease Has Caught Up with Her (2020) (0)
- Neuropathological Influences on the Clinical Phenotype of Synucleinopathies (P6.225) (2016) (0)
- THIS ISSUE: Mood Disorders in the Elderly (2004) (0)
- Olfactory Function Predicts Cognitive Deficits and Decline in Early Parkinson's Disease (S5.007) (2016) (0)
- [18F]Florbetapir PET Imaging in Cognitively Normal Parkinson’s Disease (2015) (0)
- A response to "A role for imaging and objective measures to determine increased risk of impulse control disorders in de novo Parkinson's disease" (2019) (0)
- Is sertraline treatment or depression remission in depressed Alzheimer’s patients associated with improved caregiver wellbeing? The Depression in Alzheimer’s Disease Study 2 (DIADS-2) (2014) (0)
- TV‐L1 Ordinal Logistic Regression Reveals New Morphometric Patterns Related to Parkinsonian Symptom Severity: An ENIGMA‐PD study (2022) (0)
- Cognitive Impairment as an Unexpected Guest (2020) (0)
- Amyloid-β PET imaging of Alzheimer pathology in Parkinson disease dementia (P2.180) (2015) (0)
- Author response for "Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease" (2020) (0)
- An Aptamer-Based Screen of 1000+ Plasma Proteins for Diagnostic Biomarkers in Parkinson's Disease (P4.047) (2014) (0)
- Validating virtual administration of neuropsychological testing in Parkinson disease: a pilot study (2023) (0)
- “I Keep Repeating Things to Him” (2020) (0)
- Reply to letter to the editor ‘Independent application of MoCA/MMSE conversion’ by Armstrong et al. (2015) (0)
- Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease (2016) (0)
- A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation (2015) (0)
- I Don’t Know When to Stop (2020) (0)
- EffectofCitalopramonAgitationinAlzheimerDisease The CitAD Randomized Clinical Trial (2014) (0)
- Herpes Encephalitis Recurrence? (2020) (0)
- Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. (2023) (0)
- Author response. (2013) (0)
- Parkinson’s Disease Impulsive-Compulsive Disorders Questionnaire--Current Short; Portuguese Version (2018) (0)
- Naltrexone for ICDs in PD (2020) (0)
- Screening and Treatment of Depression in Parkinson’s Disease Within Movement Disorders Centers (P7-11.015) (2023) (0)
- Increased subcortical glucose metabolism in Parkinson's disease patients with dementia (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Daniel A. Weintraub?
Daniel A. Weintraub is affiliated with the following schools:
